, Tracking Stock Market Picks
Enter Symbol:
Autodesk, Inc. (ADSK) [hlAlert]

down 43.94 %

Autodesk, Inc. (ADSK) rated Underperform by BofA/Merrill

Posted on: Friday,  Aug 24, 2012  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Autodesk, Inc. (NASDAQ: ADSK) on 08/24/2012, when the stock price was $28.03. Since
then, Autodesk, Inc. has gained 78.38% as of 11/20/2015's recent price of $50.00.
If you would have followed this BofA/Merrill's recommendation on ADSK, you would have lost 43.94% of your investment in 1183 days.

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson?s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/24/2012 8:25 AM Sell
as of 12/31/2012
1 Week up  0.92 %
1 Month down  -6.70 %
3 Months down  -5.99 %
1 YTD down  -26.11 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy